Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition

The role of microglia in the removal of amyloid deposits after systemically administered anti-Aβ antibodies remains unclear. In the current study, we injected Tg2576 APP transgenic mice weekly with an anti-Aβ antibody for 1, 2, or 3 months such that all mice were 22 months at the end of the study. In mice immunized for 3 months, we found an improvement in alternation performance in the Y maze. Histologically, we were able to detect mouse IgG bound to congophilic amyloid deposits in those mice treated with the anti-Aβ antibody but not in those treated with a control antibody. We found that Fcγ receptor expression on microglia was increased after 1 month of treatment, whereas CD45 was increased after 2 months of treatment. Associated with these microglial changes was a reduction in both diffuse and compact amyloid deposits after 2 months of treatment. Interestingly, the microglia markers were reduced to control levels after 3 months of treatment, whereas amyloid levels remained reduced. Serum Aβ levels and anti-Aβ antibody levels were elevated to similar levels at all three survival times in mice given anti-Aβ injections rather than control antibody injections. These data show that the antibody is able to enter the brain and bind to the amyloid deposits, likely opsonizing the Aβ and resulting in Fcγ receptor-mediated phagocytosis. Together with our earlier work, our data argue that all proposed mechanisms of anti-Aβ antibody-mediated amyloid removal can be simultaneously active.

[1]  D. Walsh,et al.  Species-specific immune response to immunization with human versus rodent Aβ peptide , 2004, Neurobiology of Aging.

[2]  A. McMichael,et al.  HIV vaccines 1983–2003 , 2003, Nature Medicine.

[3]  J. Schiller,et al.  Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice , 2004, BMC Neuroscience.

[4]  B. Solomon,et al.  Disaggregation of Alzheimer β-amyloid by site-directed mAb , 1997 .

[5]  J. Hardy,et al.  A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. , 2000, Nature.

[6]  D. Holtzman,et al.  Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice , 2003, Neurobiology of Disease.

[7]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[8]  Dave Morgan,et al.  Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation , 2003, The Journal of Neuroscience.

[9]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[10]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[11]  S. M. Robinson,et al.  Passage of amyloid β protein antibody across the blood–brain barrier in a mouse model of Alzheimer’s disease , 2002, Peptides.

[12]  E. Sigurdsson,et al.  Anti-prion antibodies for prophylaxis following prion exposure in mice , 2003, Neuroscience Letters.

[13]  R. Nitsch,et al.  Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease , 2002, Nature Medicine.

[14]  D. Dickson,et al.  Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/- Knock-Out Mice , 2003, The Journal of Neuroscience.

[15]  P. S. St George-Hyslop,et al.  A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. , 2000, Nature.

[16]  Jau-Shyong Hong,et al.  Molecular consequences of activated microglia in the brain: overactivation induces apoptosis , 2001, Journal of neurochemistry.

[17]  L. Manuelidis.  Vaccination with an attenuated Creutzfeldt-Jakob disease strain prevents expression of a virulent agent. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  K. Henke,et al.  Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. , 2003, Neuron.

[19]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.

[20]  R. Motter,et al.  Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[22]  D. Wilcock,et al.  Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. , 2001, DNA and cell biology.

[23]  H. Heiken,et al.  The IgG Fc receptor family , 1998, Annals of Hematology.

[24]  D. Holtzman,et al.  Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. , 2003, Neurobiology of disease.

[25]  D. Wilcock,et al.  Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration , 2004, Neurobiology of Disease.

[26]  James P. O'Callaghan,et al.  Time Course of the Development of Alzheimer-like Pathology in the Doubly Transgenic PS1+APP Mouse , 2002, Experimental Neurology.

[27]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[28]  B. Hyman,et al.  Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[29]  Xin Wu,et al.  Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.

[30]  I. Ferrer,et al.  Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease , 2004, Brain pathology.

[31]  K. Henke,et al.  Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease , 2003, Neuron.

[32]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.